Strategic Performance Drivers
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Performance exceeded expectations driven by a 16% organic growth in Proprietary Products, specifically led by a 29% surge in the Biologics market group.
High-Value Product (HVP) Components now represent 49% of total revenue, up from 46% last year, as customers increasingly shift toward advanced primary containment solutions.
Management attributes the strong win rate of over 90% for new large drug molecules to the technical necessity of barrier films like FluroTec and NovaPure for complex biologics.
The Annex 1 regulatory environment in Europe is acting as a multi-year catalyst, driving nearly 800 active upgrade projects as customers seek enhanced sterility and contamination control.
Operational excellence initiatives and a rapid recovery from a May cyber incident allowed the company to maintain throughput and capture high-teens growth in non-GLP-1 HVP components.
The company maintains a durable competitive moat by serving as the incumbent for existing drug formulations, allowing customers to upgrade to HVP finishing without re-filing stability tests.
Strategic Outlook and Guidance Assumptions
Full-year 2026 organic revenue growth guidance raised to 10% to 11%, reflecting sustained momentum in HVP Components and improved HVP Delivery Device performance.
Management expects the Annex 1 mix shift to contribute approximately 200 basis points of revenue growth in 2026, with potential for acceleration as U.S. markets adopt similar standards.
GLP-1 HVP Components are projected to maintain high-teens organic growth throughout the year, supported by Medicare expansion and the rollout of generic GLP-1s globally.
The West Vantage segment is expected to hit a revenue trough in Q3 2026 due to a contract exit, with a projected recovery in Q4 driven by the ramp-up of the drug handling business.
Operating margin expansion of over 200 basis points is anticipated for the full year, aided by the divestiture of the dilutive SmartDose 3.5mL business on July 1.
Structural Changes and Risk Factors
The divestiture of the SmartDose 3.5mL On-Body Delivery System was completed on July 1, which is expected to provide a 100 basis point margin tailwind in the second half of 2026.
A May cyber incident impacted the West Vantage segment, resulting in a mid-single-digit growth headwind in Q2 that management expects to recover in the second half of the year.
Inflationary pressures from rising oil and commodity prices are being monitored, with management planning to offset these costs through pricing actions and operational efficiencies.
The company renewed its 50-year strategic partnership with Daikyo, ensuring continued access to critical component technologies.
